InvestorsHub Logo
Followers 8
Posts 481
Boards Moderated 0
Alias Born 02/03/2021

Re: None

Friday, 07/30/2021 8:58:18 AM

Friday, July 30, 2021 8:58:18 AM

Post# of 232969
Article posted in Cytodyn website:

https://d1io3yog0oux5.cloudfront.net/cytodyn/files/pages/cytodyn/db/256/content/bmj_Edison_Long+COVID%5B5%5D.pdf

Just 2 references to Leronlimab (ctrl+f). Interestingly the article states "Leronlimab is a monoclonal antibody that blocks the function of CCL-5. It has been found to be effective and safe in HIV."

Reference to 2018 published article of Dhody, NP, Kazempour. We know the basis for this is the ph 3 trial where PE was met. Yet SEC has objected to Cytodyn making such claim. Is there a general standard in writing journal articles that we cannot say a drug has been shown to be "effective and safe" unless and until FDA actually has approved the drug? Or is it not unusual (or "illegal") for such a claim to be made based on success in ph 3 trials?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News